Education
About Us
Working with TipRanks
Follow Us
60 Degrees Pharmaceuticals, Inc. (SXTP)
:SXTP
RESEARCH TOOLSreports
SXTP Analyst Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months
SXTP Stock 12 Month Forecast
Average Price Target
$7.00
â–²(216.74%Upside)
| Highest Price Target$7.00 | Average Price Target$7.00 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts​
Detailed List of Analyst Forecasts​
TipRanks
$2.5
Sell
13.12%
Upside
Downgraded
06/12/25
The overall stock score is primarily driven by weak financial performance, as indicated by declining revenues, negative profitability, and poor cash flow. Technical indicators reflect bearish sentiment, and a negative P/E ratio points to valuation challenges. These factors collectively contribute to a low overall stock score.
Ascendiant
$7
Buy
216.74%
Upside
Reiterated
06/02/25
We are raising our FY25 EPS estimate to $(4.95) from $(5.32) on lower R&D expenses with FY25 revenue estimate of $1.4 million unchanged. We are also raising our FY26 EPS estimate to $(5.36) from $(5.72) on revenues of $2.2 million. Consensus estimates for FY25 and FY26 are $(5.59) and $(5.72) on revenues of $1.4 million $2.2 million, respectively.
H.C. Wainwright
―
Hold
―
Reiterated
03/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$2.5
Sell
13.12%
Upside
Downgraded
06/12/25
The overall stock score is primarily driven by weak financial performance, as indicated by declining revenues, negative profitability, and poor cash flow. Technical indicators reflect bearish sentiment, and a negative P/E ratio points to valuation challenges. These factors collectively contribute to a low overall stock score.
Ascendiant
$7
Buy
216.74%
Upside
Reiterated
06/02/25
We are raising our FY25 EPS estimate to $(4.95) from $(5.32) on lower R&D expenses with FY25 revenue estimate of $1.4 million unchanged. We are also raising our FY26 EPS estimate to $(5.36) from $(5.72) on revenues of $2.2 million. Consensus estimates for FY25 and FY26 are $(5.59) and $(5.72) on revenues of $1.4 million $2.2 million, respectively.
H.C. Wainwright
―
Hold
―
Reiterated
03/28/25
Best Analysts Covering 60 Degrees Pharmaceuticals, Inc.
1 Month
xxx
Success Rate
2/5 ratings generated profit
Average Return
-1.00%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -1.00% per trade.
3 Months
xxx
Success Rate
1/5 ratings generated profit
Average Return
-20.18%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 20.00% of your transactions generating a profit, with an average return of -20.18% per trade.
1 Year
Success Rate
0/5 ratings generated profit
Average Return
-75.92%
reiterated a buy rating 16 days ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -75.92% per trade.
2 Years
xxx
Success Rate
0/5 ratings generated profit
Average Return
-78.08%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -78.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SXTP Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Jun 25
Strong Buy
0
0
0
0
1
Buy
1
1
0
0
0
Hold
5
5
5
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
5
3
3
Each month's total comprises the sum of three months' worth of ratings.
SXTP Financial Forecast
SXTP Stock Forecast FAQ
What is SXTP’s average 12-month price target, according to analysts?
Based on analyst ratings, 60 Degrees Pharmaceuticals, Inc.’s 12-month average price target is 7.00.
What is SXTP’s upside potential, based on the analysts’ average price target?
60 Degrees Pharmaceuticals, Inc. has 216.74% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SXTP a Buy, Sell or Hold?
60 Degrees Pharmaceuticals, Inc. has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
What is 60 Degrees Pharmaceuticals, Inc.’s price target?
The average price target for 60 Degrees Pharmaceuticals, Inc. is 7.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 216.74% Increase from the current price of $2.21.
The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 216.74% Increase from the current price of $2.21.
What do analysts say about 60 Degrees Pharmaceuticals, Inc.?
60 Degrees Pharmaceuticals, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of SXTP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.